ULTIMOVACS ANNOUNCES AGREEMENT TO COMBINE ITS BUSINESS WITH ZELLUNA IMMUNOTHERAPY AND INTENTION TO LAUNCH FULLY COMMITTED PRIVATE PLACEMENT
17 déc. 2024 11h53 HE
|
Ultimovacs ASA
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION...
Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update
06 nov. 2024 01h00 HE
|
Ultimovacs ASA
Oslo, November 6, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its third quarter 2024 results...
Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation
31 oct. 2024 02h00 HE
|
Ultimovacs ASA
Oslo, October 31, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its third...
Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv
25 oct. 2024 11h00 HE
|
Ultimovacs ASA
Oslo, October 25, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the results from Phase II...
Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
11 sept. 2024 11h00 HE
|
Ultimovacs ASA
Oslo, September 11, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company has agreed...
Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024
08 sept. 2024 18h10 HE
|
Ultimovacs ASA
Oslo, September 9, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces the presentation of updated data...
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update
21 août 2024 01h00 HE
|
Ultimovacs ASA
Oslo, August 21, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its second quarter 2024 results...
Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation
15 août 2024 01h00 HE
|
Ultimovacs ASA
Oslo, August 15, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its second...
Ultimovacs Announces Notice of Resignation from Deputy Board Member
07 août 2024 07h59 HE
|
Ultimovacs ASA
Oslo, August 7, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI) today announced that it has received notice from deputy board member Ketil Fjerdingen that he has resigned from his position as deputy...
Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer
05 août 2024 13h12 HE
|
Ultimovacs ASA
Adding Ultimovacs’ cancer vaccine UV1 to checkpoint inhibitor pembrolizumab did not meet primary or secondary endpoints in patients with metastatic or recurrent head and neck squamous cell...